Skip to content

13F-HR filed by Casdin Capital, LLC

Casdin Capital, LLC filed this 13F-HR for the quarter ended 2017-03-31, filed 2017-05-15, with 29 holding rows worth $169,512,000.

Accession
0001172661-17-001193
Filed
2017-05-15
Accepted by EDGAR
acceptance time not in the bulk data set
Ingested
Source
SEC quarterly data set

Original filing

13F report for Q1 2017

A holdings report, 29 entries on the cover page, a total value of $169,512,000 stated on the cover page (in dollars after the unit check, H1), rows summing to $169,512,000 with VALUE read as thousands by filing date, 13F file number 028-17113. The quarter's positions are built on this report. The resolved quarter.

The information table after summing rows of one CUSIP and put or call (H4), with the CUSIP and issuer name as filed. Values in dollars after the unit check (method).

Issuer as filedCUSIPClassAmountValueValue read asType
SAGE THERAPEUTICS INC78667J108COM255,000$18,123,000thousands by filing date
Foundation Medicine Inc350465100COM480,000$15,480,000thousands by filing date
LOXO ONCOLOGY INC548862101COM360,000$15,149,000thousands by filing date
AGIOS PHARMACEUTICALS INC00847X104COM237,500$13,870,000thousands by filing date
BLUEPRINT MEDICINES CORP09627Y109COM294,500$11,777,000thousands by filing date
EVOLENT HEALTH INC CL A30050B101Stock520,000$11,596,000thousands by filing date
EPIZYME INC29428V104COM485,000$8,318,000thousands by filing date
SPARK THERAPEUTICS INC84652J103COM135,000$7,201,000thousands by filing date
VOYAGER THERAPEUTICS INC92915B106COMMON STOCK500,000$6,620,000thousands by filing date
GENMARK DIAGNOSTICS INC372309104COM400,000$5,128,000thousands by filing date
AUDENTES THERAPEUTICS INC.05070R104Common Stock260,000$4,430,000thousands by filing date
SANGAMO THERAPEUTICS INC800677106COM850,000$4,420,000thousands by filing date
VERADIGM INC01988P108COMMON STOCK310,000$3,931,000thousands by filing date
GLOBAL BLOOD THERAPEUTICS USD37890U108COM101,500$3,740,000thousands by filing date
PACIFIC BIOSCIENCES CALIF INC COM69404D108Stock700,000$3,619,000thousands by filing date
MYOKARDIA INC62857M105COM265,000$3,485,000thousands by filing date
KITE PHARMA INC49803L109COM42,500$3,336,000thousands by filing date
CODEXIS INC192005106COM675,000$3,240,000thousands by filing date
AMYRIS INC03236M101COM6,000,000$3,180,000thousands by filing date
CYTOMX THERAPEUTICS INC23284F105COMMON STOCK177,500$3,065,000thousands by filing date
EDITAS MEDICINE INC28106W103COM133,333$2,976,000thousands by filing date
SYROS PHARMACEUTICALS INC87184Q107COM182,141$2,902,000thousands by filing date
JOUNCE THERAPEUTICS INC481116101COM130,000$2,859,000thousands by filing date
ALNYLAM PHARMACEUTICALS INC COM02043Q107Stock55,000$2,819,000thousands by filing date
TESARO INC881569107COM17,500$2,693,000thousands by filing date
BLUEBIRD BIO INC09609G100COM25,500$2,318,000thousands by filing date
CLOVIS ONCOLOGY INC189464100COM23,000$1,464,000thousands by filing date
Adverum Biotechnologies, Inc.00773U108Common Stock420,000$1,134,000thousands by filing date
CURIS INC231269101COM230,000$639,000thousands by filing date

Amendment chain

FilingRoleFiledAcceptedIngested
13F-HR 0001172661-17-001193this filing2017-05-15acceptance time not in the bulk data set